Satellos Bioscience (TSE:MSCL) has released an update.
Satellos Bioscience Inc., a biotech firm focused on muscle disease treatments, reports significant muscle force improvements in a canine Duchenne muscular dystrophy study and confirms a Q3 2024 start for Phase 1 clinical trials of their leading drug SAT-3247. Additionally, the company has secured Orphan Drug and Rare Pediatric Disease designations from the US FDA and maintains a healthy cash balance of $27.7 million.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
